

107522043

STOP Rec'd PCT/P 19 JAN 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	5585-69856-01
Application Number	Not yet assigned
Filing Date	January 19, 2005
First Named Inventor	Lu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
SA		Database NCBI 'Online!' Accession No. NP_006654 (2003).
		Database NCBI 'Online!' Accession No. NP_505955 (2003).
		Bergamaschi et al., "iASPP Oncoprotein is a Key Inhibitor of p53 Conserved From Worm to Human," <i>Nature Genet.</i> 33:162-167 (2003).
		Iwabuchi et al., "Stimulation of p53-Mediated Transcriptional Activation by the p53-Binding Proteins, 53BP1 and 53BP2," <i>J. Biol. Chem.</i> 273:26061-26068 (1998).
		Naumovski and Cleary, "The p53-Binding Protein 53BP2 Also Interacts with Bcl2 and Impedes Cell Cycle Progression at G ₂ M," <i>Mol. Cell. Biol.</i> 16:3884-3892 (1996).
		Samuels-Lev et al., "ASPP Proteins Specifically Stimulate the Apoptotic Function of p53," <i>Mol. Cell</i> 8:781-794 (2001).
		Slee and Lu, "The ASPP Family: Deciding Between Life and Death After DNA Damage," <i>Toxicol. Lett.</i> 139:81-87 (2003).
		Takada et al., "RelA-Associated Inhibitor Blocks Transcription of Human Immunodeficiency Virus Type 1 by Inhibiting NF- κ B and Sp1 Actions," <i>J. Virol.</i> 76:8019-8030 (2002).

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

4/23/07

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.